Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of September 2025. The report serves to disseminate a press release issued on September 30, 2025, regarding the presentation of clinical data at the European Society of Breast Imaging Congress 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses exclusively on the dissemination of clinical study results rather than financial performance comparisons.
Guidance, Outlook, and Management Commentary
- Clinical Presentation: The Company presented positive results from five independent studies regarding its ProSense® technology at the European Society of Breast Imaging Congress 2025.
- Therapeutic Focus: The studies highlighted the potential for "de-escalation of care" in breast cancer treatment.
- Regulatory Status: The press release is incorporated by reference into the Company's active Registration Statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the specific clinical endpoints and statistical significance of the five independent studies mentioned in the press release (Exhibit 99.1).
- Confirm the regulatory implications of the "de-escalation of care" findings for future product approvals.
- Review the full text of the press release to understand the scope of the data presented, as the filing only summarizes the title and incorporation.